Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones
NCT00720031Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2000
- Primary completion
- May 2008
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Melan-A/MART-1 specific CTL clones in melanoma, sponsored by CHU de Nantes. Started Nov 2000; status: completed.
02
Drugs
Melan-A/MART-1 specific CTL clones
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00720031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720031.